Treatment Patterns and Outcomes in Patients With Lower-risk Myelodysplastic Syndromes Treated With Luspatercept in China

Bristol-Myers Squibb (BMS)

Status: Active, not recruiting

Conditions: Myelodysplastic Syndromes

Treatments: Drug: Luspatercept

Study type: Observational

Funder types: Industry

Identifiers

NCT07073690

CA056-1166

Details and patient eligibility

About

The purpose of this study is to evaluate the treatment patterns and clinical outcomes in adults with lower-risk MDS (LR-MDS) who were erythropoiesis-stimulating agents (ESA)-naïve and received luspatercept treatment in China

Enrollment: 80 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants ≥ 18 years of age.
• Documented diagnosis of no del(5q) MDS that meets lower-risk Myelodysplastic Syndromes (MDS) classification. (Diagnosis criteria and risk classification criteria are based on clinical practice)
• Patients who were erythropoiesis-stimulating agent (ESA)-naïve have received luspatercept monotherapy at least 2 cycles regardless of RS status.
• Historical documentation of anemia before luspatercept treatment.

Exclusion criteria

• Had a history of acute myeloid leukemia (AML) prior to MDS diagnosis.
• Received stem cell transplant prior to luspatercept treatment initiation.

Trial design

80 participants in 1 patient group

Participants receiving luspatercept treatment

Treatment:

Drug: Luspatercept